Vaxcyte, Inc. filings document a clinical-stage vaccine company developing bacterial-disease vaccine candidates and raising capital through registered common stock transactions. Recent Form 8-K reports cover financial results, business updates tied to VAX-31 and other pipeline programs, an underwritten common stock offering, an at-the-market sales agreement under an effective Form S-3 shelf registration, and a manufacturing services agreement for drug product supply.
Proxy materials disclose shareholder voting matters, board and governance information, executive compensation, and equity-plan matters. The filing record also identifies Vaxcyte’s Nasdaq-listed common stock under PCVX and formalizes material agreements, financing arrangements, and corporate disclosures related to its vaccine development and manufacturing strategy.
Vaxcyte, Inc. entered into a long-term Master Services Agreement with Patheon Manufacturing Services, part of Thermo Fisher Scientific, effective September 24, 2025. Patheon will formulate, fill, package, test, manufacture and supply Vaxcyte’s drug product from its Greenville, North Carolina facility.
The agreement includes binding minimum purchase commitments over defined forecast periods at established prices that may be adjusted, along with payments for technology transfer and reimbursement of certain capital expenditures. It has an initial 15-year term and automatically renews for additional three-year periods unless either party gives notice.
Vaxcyte can terminate for convenience or for specified causes, and either party may terminate for insolvency events, uncured legal or regulatory violations, or uncured material breach. If Vaxcyte terminates for convenience, it must pay Patheon at least a fixed amount in the mid-eight-figures or an amount tied to the current forecast plus certain capital commitments, with a different formula applying in the case of a defined Program Failure.
Elvia Cowan, SVP Finance at Vaxcyte, Inc. (PCVX), reported the disposition of 482 shares of the issuer's common stock on 09/08/2025 at a reported price of $32.41 per share. The filing shows 26,156 shares were beneficially owned by the reporting person after the transaction and identifies the ownership form as direct.
The form explains these 482 shares were surrendered to the company to satisfy tax-withholding obligations arising when restricted stock units vested. The Form 4 was signed on behalf of Elvia Cowan by an attorney-in-fact on 09/10/2025.
Harpreet S. Dhaliwal, listed as Chief Technical Ops Officer and a director/officer of Vaxcyte, Inc. (PCVX), reported the surrender of 1,204 shares of common stock on 09/08/2025. The transaction is coded "F" and reflects shares surrendered to the issuer to cover tax withholding obligations arising from the vesting of restricted stock units (RSUs). The reported price per share for the disposition is $32.41. Following the transaction, Dhaliwal beneficially owned 33,670 shares, held directly. The Form 4 was signed on behalf of Dhaliwal by an attorney-in-fact on 09/10/2025. The filing was made by a single reporting person.
Vaxcyte, Inc. (PCVX) insider change: Chief Operating Officer Wassil Jim reported transactions dated 09/08/2025 showing a disposition of 2,759 shares of common stock at $32.41 per share, recorded as surrendered shares to cover tax withholding on vested restricted stock units. After the reported transactions, the filing states the reporting person beneficially owned 141,848 shares. The filing also discloses a separate transfer: on 09/09/2025 the reporting person transferred 1,663 shares to an ex-spouse under a divorce settlement reflected as a domestic relations order, and those transferred shares will not be reported as beneficially owned in future Section 16 filings.
Insider transaction at Vaxcyte, Inc. (PCVX): The reporting person, Andrew Guggenhime (President and CFO), recorded a disposition of 2,890 shares of Vaxcyte common stock on 09/08/2025 at a price of $32.41 per share. After the transaction, Mr. Guggenhime beneficially owned 124,309 shares. The filing explains these shares were surrendered to the issuer to cover applicable tax withholding obligations arising when restricted stock units vested, indicating the transfer was related to tax withholding rather than an open-market sale. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person.
Grant Pickering, who is both Chief Executive Officer and a director of Vaxcyte, Inc. (PCVX), reported a transaction on 09/08/2025 in a Form 4 filing. The filing shows 7,356 shares of common stock were disposed of at $32.41 per share; the explanation states these shares were surrendered to the issuer to cover tax withholding when restricted stock units vested. After the reported transaction, Mr. Pickering beneficially owned 500,908 shares directly. The filing also discloses two trusts holding 136,215 shares each for his son and daughter. The Form 4 was signed on 09/10/2025 by an attorney-in-fact.
FMR LLC and Abigail P. Johnson disclose a 10.1% beneficial stake in Vaxcyte, Inc. The Schedule 13G/A reports combined beneficial ownership of 13,132,825.71 shares of Vaxcyte common stock. FMR LLC is shown with sole voting power over 13,090,519 shares and sole dispositive power over 13,132,825.71 shares; Abigail P. Johnson is reported with sole dispositive power for the same aggregate amount. The filing states that some other persons may have rights to dividends or sale proceeds but no other single person holds more than 5% of the class. An Exhibit 99 agreement is referenced for related identification and classification details.
Vaxcyte, Inc. SVP, Finance Elvia Cowan reported tax-withholding dispositions of a total of 567 shares of Common Stock on September 2, 2025, at $31.56 per share, surrendered to the issuer to cover tax obligations from RSU vesting. After these transactions, Cowan directly holds 26,638 shares of Common Stock.
Harpreet S. Dhaliwal, Chief Technical Ops Officer at Vaxcyte, Inc. (PCVX), reported multiple common stock dispositions on 09/02/2025. The Form 4 shows three transactions coded F that disposed of 291, 783, and 464 shares respectively at $31.56 per share to satisfy tax withholding on RSU vesting. Following these transactions, the filing reports beneficial ownership levels of 36,121, 35,338, and 34,874 shares on the respective lines. The filing also notes that 329 shares acquired under the company’s Employee Stock Purchase Plan on May 16, 2025 are included in the reported beneficial ownership figure. The Form is signed by an attorney-in-fact on behalf of Mr. Dhaliwal.
Vaxcyte, Inc. Chief Operating Officer Jim Wassil reported multiple dispositions of Vaxcyte common stock on a Form 4. On 09/02/2025 he surrendered 1,270, 1,587 and 1,429 shares (each at $31.56) to cover tax withholding upon RSU vesting, reducing reported holdings in successive lines to 149,286, 147,699 and 146,270 shares respectively. The filing also discloses a prior transfer of 1,689 shares to an ex-spouse pursuant to a divorce settlement on April 1, 2025, and notes 329 shares acquired under the Employee Stock Purchase Plan on May 16, 2025. The Form is signed by attorney-in-fact and dated 09/04/2025.